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A B S T R A C T   
Cancer cells almost universally harbor constitutively active Phosphatidylinositol-3 Kinase (PI3K) Pathway ac-
tivity via mutation of key signaling components and/or epigenetic mechanisms. Scores of PI3K Pathway in-
hibitors are currently under investigation as putative chemotherapeutics. However, feedback and stem cell 
mechanisms induced by PI3K Pathway inhibition can lead to reduced treatment efficacy. To address therapeutic 
barriers, we examined whether JAKi would reduce stem gene expression in a setting of PI3K Pathway inhibition 
in order to improve treatment efficacy. We targeted the PI3K Pathway with NVP-BEZ235 (dual PI3K and mTOR 
inhibitor) in combination with the Janus Kinase inhibitor JAKi in glioblastoma (GBM) and basal-like breast 
cancer (BBC) cell lines. We examined growth, gene expression, and apoptosis in cells treated with NVP-BEZ235 
and/or JAKi. Growth and recovery assays showed no significant impact of dual treatment with NVP-BEZ235/ 
JAKi compared to NVP-BEZ235 treatment alone. Gene expression and flow cytometry revealed that single and 
dual treatments induced apoptosis. Stem gene expression was retained in dual NVP-BEZ235/JAKi treatment 
samples. Future in vivo studies may give further insight into the impact of combined NVP-BEZ235/JAKi treat-
ment in GBM and BBC.    
Abbreviations 
PI3K: Phosphatidylinositol 3 Kinase 
PIP2: phosphatidylinositol 4,5-bisphosphate 
PIP3: phosphatidylinositol 3,4,5-trisphosphate 
AKT: protein kinase B 
FOXO: Forkhead box subfamily O 
ES: embryonic stem 
GBM: glioblastoma multiforme 
BBC: Basal breast cancer 
HER2: Human Epidermal Growth Factor Receptor 2 
OCT4: Octamer-binding Transcription factor 4 
SOX2: SRY-Box Transcription Factor 2 
MEM: minimal essential media 
DMEM: Dulbecco’s Modified Eagle Medium 
RPMI: Roswell Park Memorial Institute (RPMI) 1640 Medium 
FBS: fetal bovine serum 
PBS: Phosphate buffered saline 
NANOG: Nanog Homeobox 
ALPL: Alkaline Phosphatase Liver 
TRAIL: TNF-related apoptosis-inducing ligand 
BIM: Bcl-2-like protein 11 
FAS: TNF Receptor Superfamily, Member 6 
STAT3: Signal transducer and activator of transcription 3 
JAK2: Janus Kinase 2 
mTOR: mammalian target of rapamysin 
EGFR: Epidermal Growth Factor Receptor 
RTK: Receptor tyrosine kinase 
IBC: Institutional Biosafety Committee 
Introduction 
In 2008 Weinberg and colleagues discovered that certain poorly- 
differentiated aggressive cancers such as glioblastoma multiforme 
(GBM) and basal-like breast cancer (BBC) harbor an embryonic stem 
cell-like gene expression signature [1]. These cancers express stem genes 
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such as OCT4 (Octamer-binding Transcription Factor 4), SOX2 (SRY-Box 
Transcription Factor 2) and NANOG (Nanog Homeobox) [1-4]. Stem genes 
contribute to poor prognosis in GBM and BBC [5,6]. Of note, we and 
others found that like embryonic stem cells (ESC), the PI3K (Phospha-
tidylinositol 3-kinase) Pathway is fundamentally rewired in GBM and 
BBC [7-11]. Transcription factor FOXO1 (Forkhead box O 1) was func-
tional despite constitutively active PI3K (against the paradigm) in GBM 
and BBC [7]. Furthermore, FOXO1 promoted stem gene expression in 
GBM and BBC cancer cells via a similar mechanism described in ESC [7, 
10]. PI3K inhibitor treatment induced stem gene expression in GBM and 
BBC cells [7,8]. 
GBM is a prevalent type of tumor of the central nervous system [12, 
13]. GBM has high metastatic abilities and an aggressive phenotype 
which poses a challenge on surgical removal, giving patients an average 
15 months of survival [14,15]. Breast cancer can be classified based on 
gene expression signatures into distinct subtypes such as luminal A, 
luminal B, BBC, HER2 positive and normal-like [16-19]. BBC comprises 
approximately 10–17% of breast cancers in the United States and has 
characteristics in common with myoepithelial cells of the breast 
[20-22]. Frequently, BBC lacks expression of estrogen, progesterone and 
HER2 receptors, making these cancers unresponsive to hormonal-based 
therapies [23,24]. BBC is associated with poor prognosis [25-27]. In 
addition to harboring stem-like signatures, GBM and BBC are associated 
with self-renewal, metastasis, and chemotherapeutic resistance [1]. 
Despite therapeutic advances, targeting the bulk of tumorigenic cells 
does not exclude patients from future metastasis and relapse [28-30]. 
Targeting pathways that drive the stem signatures in GBM and BBC may 
ultimately decrease patient relapse [31-33]. 
The PI3K Pathway is almost universally activated in cancer by mu-
tations to promote growth and survival [34,35]. Endogenously, the PI3K 
Pathway is activated by growth factors binding to receptor tyrosine ki-
nases (RTKs). Active PI3K converts phosphatidylinositol-4,5, bisphos-
phate (PIP2) to phosphatidylinositol-3,4,5 trisphosphate (PIP3) [36]. 
Tumor suppressor PTEN encodes a phosphatase that converts PIP3 to 
PIP2 to down-regulate this pathway [37-39]. Second messenger PIP3 
membrane-recruits and activates AKT which phosphorylates FOXO 
transcription factors (FOXO − 1, − 3, and − 4) among other substrates 
[40]. FOXO transcription factors regulate metabolism, apoptosis, tumor 
suppression and cellular differentiation [41-43]. FOXO transcription 
factors also promote stem characteristics in embryonic stem (ES), BBC, 
and GBM cells in part by activating OCT4 gene expression [7,10]. In 
GBM and BBC, PI3K Pathway genes are characteristically mutated to 
activate signaling output. PTEN is commonly mutated to an inactive 
form, whereas the RTK gene EGFR (Epidermal Growth Factor) is mutated 
to encode an active form leading to increased growth and survival 
[44-46]. 
Given the central role of the PI3K pathway in driving tumor forma-
tion and progression, it is a common chemotherapeutic target [34, 
47-49]. PI3K pathway targeted therapies in GBM and BBC have 
improved in selectivity and stability while also decreasing in toxicity 
[50,51]. EGFR inhibitor erlotinib slowed GBM progression in a fraction 
of patients [52-54]. An enhanced PI3K inhibitor that targets both PI3K 
and mTOR (mammalian target of rapamycin), NVP-BEZ235 improved 
survival outcomes and elicited advanced antitumor effects in GBM 
[55-58]. However, we and others have observed that targeting the PI3K 
pathway leads to the induction of stem genes in GBM and BBC cells, 
potentially promoting cancer recurrence [7,8] 
Stem gene expression in GBM and BBC is activated by numerous 
mechanisms including the Janus Kinase 1/Janus Kinase 2 (JAK1/2) and 
STAT3 (Signal Transducer and Activator of Transcription 3) Pathway 
[59,60]. STAT3 is endogenously activated by JAK1/2 upon cytokine 
binding to cognate receptors. JAK1/2 phosphorylates STAT3 on tyrosine 
705, leading to homodimerization and regulation of target genes in the 
nucleus [61]. The JAK/STAT3 Pathway becomes constitutively active in 
cancer cells to accelerate tumor progression [61]. In GBM and BBC, 
activating mutations in JAK1, JAK2 and EGFR lead to constitutively 
active STAT3 [46,62-65]. Increased cytokine signaling also contributes 
to STAT3 activation in these cancers [66-69]. Active STAT3 during 
tumorigenesis contributes to proliferation and hinders apoptosis 
[70-72]. STAT3 sustains cancer stem cells and promotes metastasis 
[73-78]. In pluripotent stem cells JAK1 activates STAT3, which in turn 
directly binds to the OCT4 promoter to induce transcription [59]. 
Reduced STAT3 expression in pluripotent stem cells led to a loss in stem 
cell marker alkaline phosphatase [59]. Based on this, we reasoned that 
JAK inhibition may reduce stem characteristics in GBM and BBC cells. 
JAK inhibitors have proved effective at decreasing invasiveness and 
tumorigenesis in GBM and BBC in preclinical studies [79-81]. Pacritinib 
increased survival in GBM orthotopic xenograft studies [82]. Ruxolitinib 
decreased migration and colony formation in GBM cells [79]. AZD1480 
reduced GBM xenograft growth [83]. Similarly, JAK inhibition with 
ruxolitinib was examined as a therapeutic for BBC with limited success 
[84]. Although ruxolitinib was able to diminish STAT3 activation in 
BBC, it was not efficacious as a single agent therapy [84]. 
One barrier to effectively employing PI3K targeted therapies in GBM 
and BBC is the induction of stem genes, which may ultimately promote 
resistance and/or recurrence [7,8]. We hypothesized that targeting the 
PI3K Pathway (to suppress growth and survival) in combination with 
JAKi (to suppress growth and stem gene expression) may have a 
combinatorial impact on GBM and BBC. 
Materials and methods 
Cell culture 
Cell lines were obtained from ATCC (American Type Culture 
Collection, Manassas, VA) and grown under standard conditions (5% 
CO2, 10% FBS (fetal bovine serum), with 5% antibiotic/antimycotic 
(Thermo Fisher, Waltham, MA)). Cell lines were tested for mycoplasma 
using the MycoAlert Mycoplasma Detection Kit (Lonza, Basel 
Switzerland, cat: LT07–218); all experiments were done with myco-
plasma negative cells. U87MG cells were propagated in MEM (Minimal 
Essential Medium). DBTRG and BT549 cells were propagated in RPMI 
(Roswell Park Memorial Institute 1640 Medium). LN18, U118MG, A172, 
MDA-MB-468 and LN229 cells were propagated in DMEM (Dulbecco’s 
Modified Eagle Medium). 
Drug treatments 
Cells were plated at a density of 15,000 cells per mL and were treated 
for indicated number of days with indicated drugs for growth assays. 
Recovery assays included indicated drug treatments added to cells 
plated at 2700 cells per mL. Recovery assay samples had fresh media 
added after six days of drug treatment; these samples were allowed to 
recover for six days in fresh media before staining to assess cellular 
growth after treatment. Treatments were investigated in triplicate (in 
numerous independent experiments) and stained with crystal violet. 
Plates were aspirated of media then washed with 0.5 ml of 1x phosphate 
buffered saline (PBS) before being stained with 0.5 ml of crystal violet 
stain (0.5% crystal violet in buffered formalin) and incubated for 15 
min. The stain was aspirated, and wells were washed 3 times with 0.5 ml 
of 1x PBS. After collections were completed, crystal violet-stained plates 
were solubilized using 0.5 ml on each well of 10% acetic acid and placed 
on shaker for 1 hour. Solubilized samples were transferred to 96 well 
plates and quantified on a spectrophotometer at 590 nm. Quantified 
plates were analyzed with a Tukey Test on vassarstats.net for statistical 
significance. Error bars were added using the standard error of the 
collection readouts. NVP-BEZ235 was purchased from Sigma (Saint 
Louis, MO), and utilized at a final concentration of 50 nM in growth and 
recovery experiments. JAKi was purchased from Sigma and used at a 
final concentration of 2 μM. NVP-BEZ235 and JAKi were dissolved in 
DMSO. 
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Western blot 
Cell lines were treated with 50 nM NVP-BEZ235, 2 μM JAKi and/or 
DMSO (solvent) for 24 h. Total protein was obtained by rinsing cells 
with 1XPBS (phosphate buffered saline) followed by direct lysis in 2x 
sample buffer (125 mM Tris-HCL at pH 6.8, 2% sodium dodecyl sulfate 
(SDS), 10% 2-mercaptoethanol, 20% glycerol, 0.05% bromophenol 
blue, 8 M urea); 2x sample buffer was added to each well and cells 
scraped with a cell scraper. The lysate was collected from each well, 
placed into 1.5 mL microcentrifuge tubes and heated for 10 min at 95 ◦C 
in a dry-bath heat block. Protein lysates were separated by sodium 
dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) at 100 
V for 1 hour. The protein was then transferred onto a polyvinylidene 
fluoride (PVDF) membrane for an hour and 30 min then blocked in a 5% 
milk solution (Carnation powdered milk, 1X Tris-buffered saline with 
Tween 20 (TBST) for an hour. The membrane was incubated with 
indicated primary antibody overnight at 4 ◦C then, washed for 20 min 
with TBST in 5-minute intervals. The blot was then incubated with 
secondary antibodies for 1.5 h. The membrane was washed again for 20 
min in 5-minute intervals and allowed to develop using SuperSignal 
West Dura Extended Duration Substrate luminol solution (Pierce 
Biotechnology, Waltham, MA) for 5 min. A Bio Rad ChemDoc XRS+
Molecular Imager was utilized for protein detection (Bio Rad Hercules, 
CA). Densitometry was performed using Image Lab Software (Bio Rad 
Hercules, CA). Relative expression was calculated using total band 
volume of a protein of interest divided by the GAPDH total band volume 
for the protein sample. Band densities were depicted relative to the 
DMSO solvent control. Antibodies were obtained from Cell Signaling 
Technologies (Danvers, MA): total STAT3 (9139T), phospho STAT3 
tyrosine 705 (9145T), and phospho AKT serine 473 (9271S) and total 
AKT (4691S). GAPDH (G-9) was obtained from Santa Cruz Biotech-
nology Inc., Dallas, TX. 
Quantitative real time PCR 
Total RNA was prepared using the Qiagen RNeasy kit (Hilden, Ger-
many), which was then used to generate cDNA with Superscript Reverse 
Transcriptase II (Invitrogen, Carlsbad, CA). Samples (cDNAs) were 
analyzed using (Power SYBR Green Master Mix, Applied Biosystems, 
Foster City, CA) and the Illumina Eco Real-time system (San Diego, CA). 
Expression levels were normalized to GAPDH in gene expression ex-
periments and calculated using 2− ΔΔCT method [85]. Primer sequences 
are detailed in supplemental Table S1. All drug treatments utilized 50 
nm NVP-BEZ235 and 2 μM JAKi. Time points for RNA collection were 
optimized for each cell line. U87MG and LN229 RNA lysates were 
collected after five days of drug treatment. BT549 RNA lysates for stem 
genes were collected after five days of drug treatment. BT549 RNA ly-
sates for apoptosis were collected after 24 h. MDA-MB-468 RNA lysates 
were collected after three days of drug treatment. 
Flow cytometry 
All cell lines were treated with 50 nM NVP-BEZ235, 2 μM JAKi and/ 
or DMSO. U87MG cells were treated with drug for five days before 
assessing apoptosis, whereas LN229, BT549 and MDA-MB-468 cells 
were treated with drug for three days before assessing apoptosis. Growth 
medium was aspirated after indicated treatment. Cells were incubated 
with 2 mL of 0.25% trypsin each for 5 min at room temperature. 1.5 mL 
of each plate was transferred into 1.7 mL microcentrifuge tubes and 
centrifuged at Gx0.2 for 10 min. Trypsin supernatant was aspirated, cells 
were resuspended with 1xPBS and then centrifuged at Gx0.2 for 10 min. 
1xPBS supernatant was aspirated and cells in microcentrifuge tubes 
were then resuspended with dilute binding buffer (Molecular Probes 
FITC Annexin V/Dead Cell Apoptosis Kit from Thermo Fisher, Waltham, 
MA). 100 μl of each sample diluted with binding buffer were added to a 
fresh microcentrifuge tube. Each tube had 2 μl of Annexin V FITC and 1μl 
of PI added and incubated for 15 min in the dark. 400 μl of binding 
buffer was added after the 15-minute incubation and cells were sorted 
by BD FACS Celesta flow cytometer (BD Biosciences, San Jose, CA). 
Results 
Treatment with NVP-BEZ235 or JAKi led to a reduction in GBM and BBC 
cells 
To assess the impact of combined PI3K pathway and JAK inhibition 
on cancer cell growth and survival, we treated U87MG GBM, LN229 
GBM, BT549 BBC, and MDA-MB-468 BBC cancer cell lines with vehicle 
(DMSO), 50 nM NVP-BEZ235, and/or 2 μM JAKi (Fig. 1A-D) for five 
days. Plates were stained with crystal violet at indicated time points and 
data were analyzed by ANOVA with Tukey HSD Test. In the U87MG cell 
line on day 5, each treatment (JAKi, NVP-BEZ235 and combination of 
JAKi with NVP-BEZ235) was found to have reduced cell numbers 
compared to the DMSO vehicle (P < 0.01). JAKi single treatment had a 
significantly lower growth inhibition (P <0.01) when compared to sin-
gle NVP-BEZ235 and double treatment of JAKi/NVP-BEZ235. However, 
there was no significant difference between the single NVP-BEZ235 
treatment and the JAKi/NVP-BEZ235 double treatment for cell 
growth. In the BT549, LN229 and MDA-MB-468 cell lines on day five, 
each treatment (JAKi, NVP-BEZ235 and combination of JAKi with NVP- 
BEZ235) was found to negatively impact growth compared to the DMSO 
vehicle (P< 0.01). However, there was no significant difference between 
JAKi, NVP-BEZ235, and JAKi/NVP-BEZ235 treatments in growth assays 
(Fig. 1A-D). 
Protein lysates were utilized to assess inhibition of STAT3 (via 2 μM 
JAKi treatment) and AKT activation (via PI3K/mTOR inhibition, 50 nM 
NVP-BEZ235 treatment) with GAPDH as a loading control using western 
blot and densitometry analyses (Fig. 2A-F). Lysates collected from NVP- 
BEZ235 drug-treated samples had reduced P-AKT (S473), whereas ex-
tracts collected from the JAKi drug-treated cells showed reduced P- 
STAT3 (Y705). 
GBM cells showed reduced cell number in recovery assays with PI3K or 
JAK inhibition 
Given the similarities between the single NVP-BEZ235 combined 
NVP-BEZ235/JAKi treatments in growth assays, we sought to further 
investigate the phenotype by performing recovery assays. We treated 
indicated cell lines with vehicle (DMSO), NVP-BEZ235 alone (50 nM), 
JAKi alone (2 μM) or combined NVP-BEZ235/JAKi for six days. After 
drug treatment, we added fresh media and allowed the cells to recover 
for six days to determine differences in cell survival. The recovery assays 
would allow cytostatic cells to grow back, highlighting potential dif-
ferences between cytotoxic and cytostatic impacts. Cells were stained 
with crystal violet as described in the Materials and Methods to assess cell 
numbers following treatment and recovery. We observed significantly 
decreased cell numbers with single and double treatment samples (NVP- 
BEZ235 and/or JAKi) based on ANOVA with Tukey HSD Test with 
reference to vehicle (DMSO) controls in all cell lines examined: GBM cell 
lines U87MG, DBTRG, LN18, LN229 and U118MG, as well as BBC cell 
lines BT549 and MDA-MB-468 (Fig. 3A-G). However, there was no sig-
nificant change between NVP-BEZ235 and NVP-BEZ235/JAKi treat-
ments in recovery assays for any of the cell lines examined by Tukey HSD 
Test (Fig. 3A-G). 
Treatment with NVP-BEZ235 or JAKi led to increased apoptosis in 
examined GBM and BBC cells 
Gene expression analyses were performed to investigate mechanisms 
driving cell loss in U87MG, LN229, BT549 and MDA-MB-468 samples 
treated with the NVP-BEZ235 and/or JAKi. We initially hypothesized 
that the dual treatment would potentially cause a shift to reroute FOXO 
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factors to induce apoptotic genes at the expense of stem genes. Stem 
factor OCT4 is activated in part by STAT3 [86,87]. FOXO1 was also 
previously shown to activate OCT4 gene expression in stem cells as well 
as at least some GBM and BBC cancer cell lines [7,10]. We tracked 
apoptotic genes that FOXO factors were known to induce: TRAIL, BIM, 
and FAS[88]. We found evidence of apoptotic gene induction by each 
Fig. 1. NVP-BEZ235 or JAKi reduced Growth in Examined GBM and BBC Cell Lines A. Growth assays with U87MG cells treated with 50 nM NVP-BEZ235 and/or 2 
μM JAKi. All treatments significantly impacted growth compared to DMSO control with no increased impact from dual NVP-BEZ235/JAKi treatment (compared to 
single NVP-BEZ235 alone) based on ANOVA with Tukey HSD Test. JAKi treatment impacted growth significantly less than NVP-BEZ235. B-D. Growth assays with 
BT549, LN229 and MDA-MB-468 cells treated with 50 nM NVP-BEZ235 and/or 2μM JAKi. All treatments significantly impacted growth compared to DMSO control. 
JAKi treatment was not significantly different compared to NVP-BEZ235 or NVP-BEZ235/JAKi based on ANOVA with Tukey HSD Test. 
Fig. 2. Western Blot Analysis for NVP-BEZ235 or JAKi Treatments A. Total protein lysates were collected 24 h post NVP-BEZ235 (50 nM) and/or JAKi (2μM) 
treatment in U87MG and BT549 cells and examined by western blot analysis with indicated antibodies. B-C. Densitometry was performed using Image Lab Software 
(Bio-Rad) for U87MG and BT549 western blot data as described in the Materials and Methods. P-AKT (S473) was reduced in NVP-BEZ235 treatment samples, whereas 
P-STAT3 (Y705) was reduced in JAKi treatment samples. D. Total protein lysates were collected 24 h post NVP-BEZ235 (50 nM) and/or JAKi (2 μM) treatment in 
LN229 and MDA-MB-468 cells and examined by western blot analysis with indicated antibodies. E-F. Densitometry was performed using Image Lab Software (Bio- 
Rad) for LN229 and MDA-MB-468 western blot data. P-AKT (S473) was reduced in NVP-BEZ235 treatment samples, whereas P-STAT3 (Y705) was reduced in JAKi 
treatment samples. 
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drug treatment in each of the cell lines examined compared to DMSO 
controls, except for JAKi and combined NVP-BEZ235/JAKi treatments 
in MDA-MB-468 (Figs. 4A-B and S1 A-B). In contrast to our hypothesis, 
all examined cell lines retained OCT4 expression as a stem marker in 
combination NVP-BEZ235/JAKi treated samples (Figs. 4C-D and S1 
C-D). Some of the cell lines retained expression of additional markers 
such as SOX2, NANOG and ALPL (Alkaline Phosphatase Biomineralization 
Associated), (Figs. 4C-D and S1 C-D). Therefore, the combined 
NVP-BEZ235/JAKi treatment succeeded at inducing apoptotic genes but 
failed to suppress stem gene expression. 
Fig. 3. NVP-BEZ235 or JAKi treatment reduced cell numbers in recovery assays. Recovery assays were performed with GBM and BBC cell lines in which cells were 
treated with indicated drugs for six days and were then allowed to recover in complete media without drug for six days. A-G. All drug treatments in each examined 
cell line significantly impacted cell numbers compared to DMSO control (denoted *), with no increased impact from dual NVP-BEZ235/JAKi treatment compared to 
NVP-BEZ235 alone based on ANOVA with Tukey HSD Test. NVP-BEZ235 was abbreviated NVP. MDA-MB-468 was abbreviated 468. 
Fig.. 4. Treatment of examined GBM or BBC cells with Dual PI3K Inhibitor NVP-BEZ235 and/or JAKi Induced Apoptotic Gene Expression. A-B. Gene expression of 
FOXO-induced apoptotic targets (determined by qRT-PCR relative to GAPDH control) in U87MG and BT549 cells. NVP-BEZ235 treatment led to induction of BIM and 
TRAIL. C. Expression of stem genes from drug treatment samples by qRT-PCR (relative to GAPDH control). Stem genes OCT4, SOX2, NANOG and ALPL were induced 
in U87MG NVP-BEZ235 treatment samples with or without JAKi. Single agent treatment with JAKi led to reduced SOX2 and NANOG. D. Expression of OCT4 and 
NANOG in BT549 cells with indicated drug treatments. OCT4 and NANOG remained induced with the combined NVP-BEZ235/JAKi treatment based on ANOVA with 
Tukey HSD Test (denoted *). 
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To further examine apoptotic induction by NVP-BEZ235 and/or JAKi 
treatment, we performed flow cytometry. The marker for early apoptosis 
annexin-V conjugated with green fluorescent dye FITC was used to bind 
to externally exposed phospholipid phosphatidylserine thereby detect-
ing membrane depolarization [89]. A DNA intercalating agent and late 
marker of apoptosis propidium iodide (PI) was used to detect cell 
permeability [90]. Cells stained with annexin-V FITC and/or PI were 
counted as apoptotic. Treatment with NVP-BEZ235 alone or the com-
bination of NVP-BEZ235/JAKi led to similar levels of apoptosis in BT549 
cells compared to DMSO controls (Fig. 5A-E). JAKi alone, NVP-BEZ235 
alone, and combined NVP-BEZ235/JAKi treatments (compared to 
DMSO control) led to apoptotic induction in U87MG, LN229 and 
MDA-MD-468 cell lines based on ANOVA with Tukey HSD Test (Fig. 5E). 
Conclusion 
The PI3K Pathway is almost universally constitutively active in GBM 
and BBC due to pathway mutations [37,44,46]. Activation of the PI3K 
Pathway drives tumor formation, progression, and metastasis, making it 
an ideal target for therapeutic intervention [34,36,47]. The use of PI3K 
inhibitors to treat GBM and BBC was previously shown to significantly 
induce cell death [91-93]. Cell cycle arrested remnants could develop 
resistance to treatments to become metastatic [94]. The 50 nM dose of 
NVP-BEZ235 employed in this work was utilized in clinical settings and 
pre-clinical studies [55,56]. Similar doses of NVP-BEZ235 examined in 
GBM cell lines (U87MG, U251, T98G and SGH44) induced G1 cell cycle 
arrest and apoptosis [55]. NVP-BEZ235 treatment also reduced che-
moresistance to temozolomide in GBM models and enhanced radiosen-
sitivity of GBM stem cells [55,56]. Low doses of NVP-BEZ235 (10–100 
nM) led to either growth arrest or cell death in BBC cell lines [95,96]. 
STAT3 inhibition led to a decrease in temozolomide resistance in GBM 
[97]. Likewise, inhibition of JAK/STAT led to decreased invasiveness in 
GBM and BBC [83,84]. Our study employed 2μM JAKi based on work by 
Marotta et al. in a BBC setting [78]. Clinical trials are underway to 
examine the impact of JAK inhibition as a therapeutic for GBM and BBC 
[79,84]. 
Although the combined treatment of NVP-BEZ235/JAKi had a 
limited impact in our study, others have found potent efficacies in acute 
lymphoblastic leukemia and B cell malignancies [98-100]. Signaling 
redundancies that induce stem characteristics may underpin the lack of 
efficacy in GBM and BBC cells. 
Examined GBM and BBC cells retained expression of stem genes in 
dual treatment (NVP-BEZ235 and JAKi) samples. Therefore, inhibition 
of JAKi was not sufficient to block stem gene expression in the NVP- 
BEZ235 treated samples (Fig. 4C-D and S1 C-D). The impact of STAT3 
on stem gene expression is context dependent [59,101,102]. It remains 
to be determined if the increase in stem gene expression with 
NVP-BEZ235 treatment resulted from the survival of cells that express 
stem genes (such as cancer stem cells surviving and non-cancer stem 
cells undergoing apoptosis), leading to an enrichment in cancer stem 
cells. Alternatively, JAK-independent mechanisms may drive stem gene 
expression in this setting or the cells that express these stem genes may 
be resistant to drug treatment (perhaps via drug efflux). The timing of 
drug treatment may also contribute to therapeutic efficacy. Treatment of 
GBM with NVP-BEZ235 for one hour prior to with ionizing radiation 
strongly enhanced radiosensitivity [103]. In contrast, a 24-hour 
NVP-BEZ235 treatment prior to IR treatment led to G1 arrest and 
exhibited less DNA damage; there was no enhancement of IR sensitivity 
with the 24-hour treatment [103]. Delineating molecular mechanisms 
that drive stem characteristics and therapeutic resistance is key to 
improving chemotherapeutic efficacy for GBM and BBC. 
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